These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8651586)

  • 1. Biological staging of incipient, in situ, and invasive breast carcinomas.
    Querzoli P; Albonico G; Ferretti S; Rinaldi R; Nenci I
    Ann N Y Acad Sci; 1996 Apr; 784():381-94. PubMed ID: 8651586
    [No Abstract]   [Full Text] [Related]  

  • 2. Microinvasive lobular carcinoma of the breast.
    Howat AJ; Armour A; Ellis IO
    Histopathology; 2000 Nov; 37(5):477-8. PubMed ID: 11119139
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptors for estrogen and progesterone in breast carcinoma in situ.
    Pallis L; Wilking N; Cedermark B; Rutqvist LE; Skoog L
    Anticancer Res; 1992; 12(6B):2113-5. PubMed ID: 1295456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up.
    Wynveen CA; Nehhozina T; Akram M; Hassan M; Norton L; Van Zee KJ; Brogi E
    Am J Surg Pathol; 2011 Jan; 35(1):1-14. PubMed ID: 21084964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of age: breast cancer presents differently in young women.
    Oncology (Williston Park); 1994 Nov; 8(11):15-6. PubMed ID: 7826835
    [No Abstract]   [Full Text] [Related]  

  • 9. [Steroid hormone receptors in mammary carcinoma. Immunohistochemical detection and prognostic significance].
    Reiner A; Neumeister B; Reiner G; Jakesz R; Kolb R; Schemper M; Spona J
    Zentralbl Pathol; 1991; 137(3):233-41. PubMed ID: 1657132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant expression of IGFBP2 in breast cancer compared with benign lesions.
    Busund LT; Richardsen E; Busund R; Ukkonen T; Bjørnsen T; Busch C; Stalsberg H
    J Clin Pathol; 2005 Apr; 58(4):361-6. PubMed ID: 15790698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
    Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
    Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast.
    Bur ME; Zimarowski MJ; Schnitt SJ; Baker S; Lew R
    Cancer; 1992 Mar; 69(5):1174-81. PubMed ID: 1739917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology role in adjuvant setting.
    Reiner-Concin A
    Cancer Treat Res; 2009; 151():41-61. PubMed ID: 19593505
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of hormonal status on thermography findings in breast cancer.
    Zore Z; Boras I; Stanec M; Oresić T; Zore IF
    Acta Clin Croat; 2013 Mar; 52(1):35-42. PubMed ID: 23837271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.
    Liu F; Cui L; Zhang Y; Chen L; Wang Y; Fan Y; Lei T; Gu F; Lang R; Pringle GA; Zhang X; Chen Z; Fu L
    Breast Cancer Res Treat; 2010 Dec; 124(3):677-88. PubMed ID: 20213083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantages of an immunohistochemical estrogen receptor assay.
    Judd R
    South Med J; 1991 Jul; 84(7):853-6, 861. PubMed ID: 2068625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between estrogen and progesterone receptors and certain pathologic features with prognostic significance in primary invasive breast carcinomas.
    Santini D; Ricci M; Di Palma S; Taffurelli M; Grassigli A; Marrano D
    Arch Anat Cytol Pathol; 1986; 34(2):85-8. PubMed ID: 3777995
    [No Abstract]   [Full Text] [Related]  

  • 18. Signet-ring cell carcinoma of the breast.
    Liu SM; Chen DR
    Pathol Int; 2000 Jan; 50(1):67-70. PubMed ID: 10692181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Occult multicentric breast cancer].
    Vtorushin SV; Zab'ialova MV; Glushchenko SA; Perel'muter VM; Slonimskaia EM
    Vopr Onkol; 2009; 55(1):38-41. PubMed ID: 19435197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features.
    Ishikawa Y; Horiguchi J; Toya H; Nakajima H; Hayashi M; Tagaya N; Takeyoshi I; Oyama T
    Cancer Sci; 2011 Mar; 102(3):656-62. PubMed ID: 21214677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.